Paper36735694
Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data.
Kim J and 3 others. PLoS One, 2023. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data. Papers, record 36735694. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36735694
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Tapering | Major topic |
| Idiopathic Pulmonary Fibrosis | Major topic |
| Humans | |
| Aged | |
| Retrospective Studies | |
| Anti-Inflammatory Agents, Non-Steroidal | |
| Pyridones | |
| Treatment Outcome | |
| Vital Capacity |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32297284 | Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients. | Adv Ther | 2020 | https://conductscience.org/library/papers/32297284 | PubMed |
| 2 | 24836312 | A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24836312 | PubMed |
| 3 | 34941933 | Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study. | PLoS One | 2021 | https://conductscience.org/library/papers/34941933 | PubMed |
| 4 | 29212837 | Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. | Eur Respir Rev | 2017 | https://conductscience.org/library/papers/29212837 | PubMed |
| 5 | 25115833 | Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. | Respiration | 2014 | https://conductscience.org/library/papers/25115833 | PubMed |
| 6 | 30470213 | Pirfenidone improves survival in IPF: results from a real-life study. | BMC Pulm Med | 2018 | https://conductscience.org/library/papers/30470213 | PubMed |
| 7 | 19420141 | Adverse drug reactions in elderly: challenges in identification and improving preventative strategies. | Age Ageing | 2009 | https://conductscience.org/library/papers/19420141 | PubMed |
| 8 | 33277557 | Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital. | Sci Rep | 2020 | https://conductscience.org/library/papers/33277557 | PubMed |
| 9 | 9713446 | Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. | Thorax | 1998 | https://conductscience.org/library/papers/9713446 | PubMed |
| 10 | 21571362 | Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. | Lancet | 2011 | https://conductscience.org/library/papers/21571362 | PubMed |
| 11 | 19996196 | Pirfenidone in idiopathic pulmonary fibrosis. | Eur Respir J | 2010 | https://conductscience.org/library/papers/19996196 | PubMed |
| 12 | 24639005 | Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. | Adv Ther | 2014 | https://conductscience.org/library/papers/24639005 | PubMed |
| 13 | 30665416 | Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. | Respir Res | 2019 | https://conductscience.org/library/papers/30665416 | PubMed |
| 14 | 23056564 | Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. | PLoS One | 2012 | https://conductscience.org/library/papers/23056564 | PubMed |
| 15 | 27876247 | Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. | Lancet Respir Med | 2017 | https://conductscience.org/library/papers/27876247 | PubMed |
| 16 | 28843616 | Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study. | Pulm Pharmacol Ther | 2017 | https://conductscience.org/library/papers/28843616 | PubMed |
| 17 | 25712077 | Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. | Eur Heart J Cardiovasc Imaging | 2015 | https://conductscience.org/library/papers/25712077 | PubMed |
| 18 | 20935110 | Clinical course and prediction of survival in idiopathic pulmonary fibrosis. | Am J Respir Crit Care Med | 2011 | https://conductscience.org/library/papers/20935110 | PubMed |
| 19 | 31999801 | Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice. | PLoS One | 2020 | https://conductscience.org/library/papers/31999801 | PubMed |
| 20 | 26344613 | All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. | Respir Investig | 2015 | https://conductscience.org/library/papers/26344613 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41995999 | Efficacy and tolerability of generic pirfenidone after switch from Esbriet® in idiopathic pulmonary fibrosis: a real-world observational study. | Intern Emerg Med | 2026 | https://conductscience.org/library/papers/41995999 | PubMed |
| 40356972 | Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40356972 | PubMed |
| 39512192 | Real-world therapeutic performance of pirfenidone for connective tissue disease-associated interstitial lung diseases. | Ther Adv Respir Dis | 2024 | https://conductscience.org/library/papers/39512192 | PubMed |
| 38963453 | Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. | Eur J Clin Pharmacol | 2024 | https://conductscience.org/library/papers/38963453 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GPT | 2875 | PubTator's text mining | https://conductscience.org/library/genes/2875 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36735694
GET https://conductscience.org/api/papers/v1/36735694/references?page=2